Bioconversion of inulin to difructose anhydride III by a novel inulin fructotransferase from Arthrobacter chlorophenolicus A6

Tailored Enzymes for Difructose Anhydrides: From Biosynthesis to Degradation

Difructose anhydrides (DFAs), distinctive cyclic disaccharides mainly naturally produced by heating (caramelization), serve as potential candidates of functional sugars that modern humans consume on a daily basis due to their remarkable physiological effects. This review explores the complex domain of specialized enzymes implicated in the metabolism of DFAs, covering the entire process from biosynthesis to degradation. We provide a detailed examination of the enzymes responsible for DFA formation and degradation, specifically those classified within the GH91, GH32, and GH172 glycoside hydrolase families. Furthermore, the evolutionary relationships among the related enzymes were systematically analyzed. Subsequently, the underlying enzymatic mechanisms that drive DFAs' metabolism were elucidated, and key insights into the intricate interplay between enzyme structure and function were unveiled. Additionally, innovative strategies for enzyme engineering were discussed, aimed at improving thermostability, enhancing catalytic activity, and altering catalytic function. Finally, the applications of the related enzymes were comprehensively summarized with a focus on their product yields, conversion rates, and methods for product purification. Here, the review presents a comprehensive investigation into enzymatic degradation and biosynthesis pathways of DFAs.

Verification of utilization ability of Bifidobacterium and Lactobacillus to difructose anhydride III in vitro by its hydrolases and their application in Jerusalem artichoke tuber to improve nutrition

The functional Difructose anhydride III (DFA-III) lacks reported utilization by special probiotics of Bifidobacterium and Lactobacillus. DFA-III hydrolase (DFA-IIIase), converting DFA-III to inulobiose, is a critical enzyme for the metabolism of DFA-III, which stands for the utilization ability of DFA-III by microorganisms. Hence, the research identified six potential DFA-IIIases from Bifidobacterium and Lactobacillus species, suggesting that DFA-III has the potential to proliferate these bacteria. Notably, the DFA-IIIase from Bifidobacterium adolescentis belonging to the human intestinal microbe exhibits a hydrolysis rate of up to 67 % for DFA-III, which is the highest among the reported DFA-IIIases to date. When DFA-IIIases were applied to Jerusalem artichokes, DFA-III, inulobiose, and fructo-oligosaccharides were significantly produced. The in vitro work indicates that Bifidobacterium and Lactobacillus have the potential ability to utilize DFA-III by DFA-IIIases. Moreover, the first application of DFA-IIIase in Jerusalem artichokes provides valuable insights into comprehensive strategies for utilizing high-inulin agricultural products.

Production and Bioconversion Efficiency of Enzyme Membrane Bioreactors in the Synthesis of Valuable Products

The demand for bioactive molecules with nutritional benefits and pharmaceutically important properties is increasing, leading researchers to develop modified production strategies with low-cost purification processes. Recent developments in bioreactor technology can aid in the production of valuable products. Enzyme membrane bioreactors (EMRs) are emerging as sustainable synthesis processes in various agro-food industries, biofuel applications, and waste management processes. EMRs are modified reactors used for chemical reactions and product separation, particularly large-molecule hydrolysis and the conversion of macromolecules. EMRs generally produce low-molecular-weight carbohydrates, such as oligosaccharides, fructooligosaccharides, and gentiooligosaccharides. In this review, we provide a comprehensive overview of the use of EMRs for the production of valuable products, such as oligosaccharides and oligodextrans, and we discuss their application in the bioconversion of inulin, lignin, and sugars. Furthermore, we critically summarize the application and limitations of EMRs. This review provides important insights that can aid in the production of valuable products by food and pharmaceutical industries, and it is intended to assist scientists in developing improved quality and environmentally friendly prebiotics using EMRs.

Biosynthesis of lactosucrose by a new source of β-fructofuranosidase from Bacillus methanolicus LB-1

Lactosucrose (LS) is a prebiotic trisaccharide enzymatically synthesized by transglycosylation from lactose and sucrose with beneficial health effect. The β-fructofuranosidase used for synthesis of LS was produced from Bacillus methanolicus LB-1, which was isolated from traditional rice wine. A maximal yield of 8.63 U/mL of the enzyme was obtained by fermentation with B. methanolicus LB-1 under the optimized conditions: 10 g/L of glucose, 5 g/L of yeast extract, initial medium pH at 7.0, 37 °C, 24 h. The enzyme was purified and identified by ammonium sulfate fractional precipitation, Sephadex G-75 gel filtration chromatography and LC-MS, and SDS-PAGE of the purified enzyme showed a major protein band at 45 kDa. Biosynthesis of LS was performed using the purified β-fructofuranosidase, and production of LS reached 110 g/L under the optimized reaction conditions: pH at 7.0, 37 °C, 6.0 U/g sucrose of enzyme, 15% of sucrose, 15% of lactose, 28 h. HPLC analysis of the reaction products showed a distinct peak for LS at about 30 min of elution, confirming that B. methanolicus LB-1 β-fructofuranosidase had effective transfructosylation activity. Therefore, this new microbial source of β-fructofuranosidase may be a candidate with potential application prospect in biosynthesis of prebiotic LS.

Difructose anhydride III: a 50-year perspective on its production and physiological functions

Production and applications of difructose anhydride III (DFA-III) have attracted considerable attention because of its versatile physiological functions. Recently, large-scale production of DFA-III has been continuously explored, which opens a horizon for applications in the food and pharmaceutical industries. This review updates recent advances involving DFA-III, including: biosynthetic strategies, purification, and large-scale production of DFA-III; physiological functions of DFA-III and related mechanisms; DFA-III safety evaluations; present applications in food systems, existing problems, and further research prospects. Currently, enzymatic synthesis of DFA-III has been conducted both industrially and in academic research. Two biosynthetic strategies for DFA-III production are summarized: single- and double enzyme-mediated. DFA-III purification is achieved via yeast fermentation. Enzyme membrane bioreactors have been applied to meet the large-scale production demands for DFA-III. In addition, the primary physiological functions of DFA-III and their underlying mechanisms have been proposed. However, current applications of DFA-III are limited. Further research regarding DFA-III should focus on commercial production and purification, comprehensive study of physiological properties, extensive investigation of large-scale human experiments, and expansion of industrial applications. It is worthy to dig deep into potential application and commercial value of DFA-III.